Living donor liver transplantation for hemophilia with special reference to the management of perioperative clotting factor replacement

Togashi, Junichi; Akamatsu, Nobuhisa; Tanaka, Tomohiro; Sugawara, Yasuhiko; Tsukada, Kunihisa; Kaneko, Junichi; Arita, Junichi; Sakamoto, Yoshihiro; Hasegawa, Kiyoshi

doi:10.1002/lt.24341

Cited by 11 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, the post‐transplant survival rates appears similar between PWH and non‐haemophiliacs 113,114 . In various studies, the post‐transplant survival rate for PWH after 1, 3 and 5 years range between 78% and 90%, 67–80% and 54–67%, respectively 111,113–115 . PWH undergoing OLT now are likely to have an improved survival rate compared to these historical cohorts.…”

Section: Liver Transplantation In Haemophiliamentioning

confidence: 91%

“…113,114 In various studies, the post-transplant survival rate for PWH after 1, 3 and 5 years range between 78% and 90%, 67-80% and 54-67%, respectively. 111,[113][114][115] PWH undergoing OLT now are likely to have an improved survival rate compared to these historical cohorts. The most common cause of death after OLT in these studies was liver failure due to recurrent HCV or HCC, 24,111,113 for which many new treatment options have become available recently.…”

Section: Liver Transplantation In Haemophiliamentioning

confidence: 99%

See 1 more Smart Citation

Viral hepatitis in haemophilia: historical perspective and current management

et al. 2021

View full text Add to dashboard Cite

The introduction of clotting factor concentrates has substantially improved the lives of people with clotting factor deficiencies. Unfortunately, the transmission of blood-borne viral infections through these plasma-derived products led to a huge epidemic of human immunodeficiency virus and viral hepatitis in people with haemophilia (PWH). In a significant proportion of PWH exposed to these viruses, the ensuing decades-long chronic infection resulted in excess morbidity and mortality. Fortunately, developments in the safety of blood products, as well as vaccination and highly effective antiviral treatments have improved the prospects of PWH. The present article reviews the background of the viral hepatitis epidemic in PWH, the natural history of hepatitis B and C infections and their long-term management.

show abstract

Section: Liver Transplantation In Haemophiliamentioning

confidence: 91%

Section: Liver Transplantation In Haemophiliamentioning

confidence: 99%

Viral hepatitis in haemophilia: historical perspective and current management

et al. 2021

View full text Add to dashboard Cite

show abstract

“…If the donor does not have hemophilia, the transplanted liver will produce the coagulation factor previously deficient in the recipient with hemophilia, and the recipient may no longer need treatment with coagulation factor preparations. However, it has been reported that coagulation factor production may be insufficient when the liver donor is deceased or is a hemophilia carrier (8). In our case, as in others, immunosuppressive treatment was continued during the perioperative period.…”

Section: Discussionmentioning

confidence: 49%

Anesthesia management of arthroscopic ankle arthrodesis for a hemophilia patient after living-donor liver transplantation

Shibata

Orii

Ako

2019

IRDR

View full text Add to dashboard Cite

“…Liver transplantation for hemophilia has a greater risk of intra- and postoperative bleeding. Several reports have discussed the efficacy of the administration of recombinant factor by continuous and/or bolus infusion as a bridge until a newly transplanted liver begins to produce and maintain adequate factor IX activity [ 31 – 33 ]. In this case, we could control intra-operative hemostasis well by the combination of the continuous infusion and intermittent bolus infusion with close monitoring.…”

Section: Discussionmentioning

confidence: 99%

Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Outcome of the liver transplantation (LT) is worse in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients compared to patients infected with HCV alone. We report the world's first case of living donor domino liver transplantation (LDDLT) using a familial amyloid polyneuropathy (FAP) liver in a coinfected recipient with HCV-related liver cirrhosis. Case presentation: The recipient was a 43-year-old male with a CD4 cell count of 52/μL and undetectable HIV-RNA at the time of LT. He received a domino liver graft from a 41-year-old female with FAP. No acute cellular rejection or infection occurred after LT. HCV recurrence was confirmed histologically on the posttransplant day 34. Peginterferon/ ribavirin therapy resulted in non-response; however, the patient achieved a sustained viral response with sofosbuvir (SOF)/ledipasvir (LDV). Currently, HCV and HIV testing are negative, and symptomatic de novo amyloidosis has not occurred. Conclusions: LDDLT allows successful LT in HCV/HIV-coinfected patients; posttransplant HCV recurrence can be successfully treated with anti-viral therapy.

show abstract

Living donor liver transplantation for hemophilia with special reference to the management of perioperative clotting factor replacement

Cited by 11 publications

References 7 publications

Viral hepatitis in haemophilia: historical perspective and current management

Viral hepatitis in haemophilia: historical perspective and current management

Anesthesia management of arthroscopic ankle arthrodesis for a hemophilia patient after living-donor liver transplantation

Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report

Contact Info

Product

Resources

About